Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps
stop the growth of cancer and abnormal cells and helps stop the patient's immune system from
rejecting the donor's stem cells. When the stem cells from an unrelated donor, that do not
exactly match the patient's blood, are infused into the patient they may help the patient's
bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
transplanted cells from a donor can make an immune response against the body's normal cells.
Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil
after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well donor umbilical cord blood stem cell
transplant works in treating patients with hematologic malignancies.